Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884597 · ClinicalTrials.gov registry record · Phase 1
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
A Phase 1 study, sponsored by Hawaii Pacific Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01884597 is a Phase 1 study that has completed, run by Hawaii Pacific Health. The registered enrollment target is 24 participants.
The verdict
NCT01884597, a Phase 1 study, has completed, sponsored by Hawaii Pacific Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.
Interventions
- DRUG ranibizumab
- DRUG high-dose ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01884597
The ClinicalTrials.gov registry entry for NCT01884597 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hawaii Pacific Health, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ranibizumab is the first listed.
NCT01884597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01884597 about?
NCT01884597 is a clinical study titled "Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)". This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.
What is the current status of trial NCT01884597?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-11. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01884597?
The interventions under investigation include: ranibizumab (DRUG), high-dose ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01884597?
This trial is sponsored by Hawaii Pacific Health, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.